What is HC Wainwright’s Estimate for MNPR FY2029 Earnings?

Monopar Therapeutics Inc. ( NASDAQ:MNPR – Free Report ) – Analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Monopar Therapeutics in a research note issued to investors on Tuesday, April 1st. HC Wainwright analyst S.

Lee now expects that the company will post earnings of $3.35 per share for the year, down from their previous forecast of $3.66.



HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.

65) per share. Several other brokerages have also recently weighed in on MNPR. Jones Trading reiterated a “hold” rating on shares of Monopar Therapeutics in a research report on Wednesday.

Piper Sandler restated an “overweight” rating and set a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company.

According to MarketBeat, Monopar Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $44.00. Monopar Therapeutics Price Performance Shares of MNPR opened at $34.

59 on Wednesday. The stock’s fifty day moving average price is $38.52 and its two-hundred day moving average price is $24.

70. Monopar Therapeutics has a 1 year low of $1.72 and a 1 year high of $54.

30. The firm has a market cap of $211.45 million, a PE ratio of -17.

56 and a beta of 1.01. Monopar Therapeutics ( NASDAQ:MNPR – Get Free Report ) last posted its earnings results on Monday, March 31st.

The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.

87). Institutional Trading of Monopar Therapeutics A number of hedge funds and other institutional investors have recently modified their holdings of MNPR. JPMorgan Chase & Co.

purchased a new stake in Monopar Therapeutics during the 4th quarter valued at about $45,000. Geode Capital Management LLC lifted its stake in shares of Monopar Therapeutics by 174.4% in the 4th quarter.

Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after purchasing an additional 24,530 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Monopar Therapeutics during the 4th quarter valued at $2,861,000. Point72 Asset Management L.

P. purchased a new stake in Monopar Therapeutics in the fourth quarter worth about $3,694,000. Finally, RA Capital Management L.

P. bought a new stake in Monopar Therapeutics during the 4th quarter worth approximately $11,247,000. 1.

83% of the stock is owned by hedge funds and other institutional investors. Monopar Therapeutics Company Profile ( Get Free Report ) Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Read More Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..